Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
about
The PTEN tumor suppressor gene and its role in lymphoma pathogenesisProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerDiscovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.Therapeutic targeting of cancers with loss of PTEN function.Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodesPTEN mediates Notch-dependent stalk cell arrest in angiogenesisEffects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.PI3K: from the bench to the clinic and back.PI3Kα inhibitors that inhibit metastasis.Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatmentThe enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell typesPleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?Biological Relevance and Therapeutic Potential of the Hypusine Modification System.Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations.Lentiviral vector PLV-PI3KCG gene transfer inhibits hypoxic cardiomyocytes apoptosis.p110δ PI3 kinase pathway: emerging roles in cancer.P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapsePI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.PI3K pathway dependencies in endometrioid endometrial cancer cell lines.Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion.Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.Personalized therapies in the cancer "omics" eraProgress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Emerging targeted agents in metastatic breast cancer.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network.Drugging PI3K in cancer: refining targets and therapeutic strategiesCharacterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.RIST: a potent new combination therapy for glioblastoma.Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
P2860
Q26776527-1CF6E26C-A6AD-4666-8096-9EC213B3865AQ26852215-65CDD297-6BD8-47E6-ABE5-C41384D96501Q27711042-21BE3B0A-6615-452E-B994-E058DD5516BBQ27852473-65BF603E-C0DE-4A6F-A8E2-51F2F364CCDBQ27852764-EFBE6020-BE43-4020-B7ED-DA68BB375DB3Q27853093-A6DFA55A-181A-41B5-83C7-082195A943C3Q28730141-0E40EF60-305B-4E78-A107-2718CEF3D28EQ33663049-5DEE7DE6-355F-469F-B75F-6EDC8F91E80AQ33734538-BBB7CE5C-D0ED-4F55-BB24-1901D228CA05Q34195495-C3BDE8DB-A374-4A0D-ABC9-8826D19A146EQ34416746-85F236D6-ABC4-4B39-853D-6D800E445373Q34508976-7AAFAF0F-4150-47BA-A36B-F595AAE35286Q35067622-1A0EBAEE-AAD5-432E-B994-87C5262C1C98Q35215580-F9C0AE3E-BCEA-4FC0-A93D-49DCAA0FB0E5Q35287780-25CF2958-E39D-463A-A2A2-BFB93C57DA76Q35883784-9D1EB721-1D71-441B-9444-A8F232E1ED90Q36088956-9762AC9F-986B-4C87-AC95-96FEC7181AD6Q36492661-3C7449B4-88EE-484A-83EE-C84FC36A6D13Q36647928-61B80E64-A379-432B-B136-5D706D6594B6Q36709839-00093B3D-1C88-447C-A492-EDF41C00135FQ36899519-D6DF8376-4954-4631-A4E5-04F1C6365D7FQ36980561-6DB9F802-4318-43E9-9F75-9D3DF3FCECC8Q37109616-0D1F0D9E-A481-43E8-858A-9514F1C6025AQ37421296-88A5EF4A-205B-4CFC-B41C-6A29DAA04B7BQ37729587-53D374ED-D56B-44FE-8E6D-86689AA5358BQ37776547-1471E939-0006-4B7A-8266-2331361B4474Q37886009-336038A5-1D10-461E-9D7E-BBAF2247987AQ37976467-A7E0E86B-5BB2-476A-9989-2663E9D2964CQ38042638-2186776B-681D-480F-A9DF-2232D98B74FBQ38086421-B0767B4B-19C7-4910-AA2D-AB2618454A02Q38371672-5EB74FCC-6217-4E13-8643-8556C68EB0A8Q38391539-79077907-BD75-4E46-BE35-E8B154B17B1CQ38539217-17C95533-4AFC-4352-8C56-54A72551EB3AQ38699761-D8307DCF-2F8F-42DC-AD9C-81334851FAEBQ38710557-8537BC74-44D9-46C3-8B5B-0F703F8397CDQ38825945-8FBAFCDA-D8A9-4AB4-A680-B3E6181E3FEBQ38852858-4C0593EC-7917-48F3-B169-204A95E88A1FQ38966022-5713D624-A463-487B-96C1-8AD83A0A022BQ39094806-38E1273E-C84E-4708-894B-855890EF9161Q39218787-805CC8CE-AA27-48C2-BF68-14029B2DD895
P2860
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Isoform-specific phosphoinosit ...... tinct effects in solid tumors.
@en
Isoform-specific phosphoinosit ...... tinct effects in solid tumors.
@nl
type
label
Isoform-specific phosphoinosit ...... tinct effects in solid tumors.
@en
Isoform-specific phosphoinosit ...... tinct effects in solid tumors.
@nl
prefLabel
Isoform-specific phosphoinosit ...... tinct effects in solid tumors.
@en
Isoform-specific phosphoinosit ...... tinct effects in solid tumors.
@nl
P2093
P1433
P1476
Isoform-specific phosphoinosit ...... tinct effects in solid tumors.
@en
P2093
Deepak Sampath
Jeffrey J Wallin
Kyle A Edgar
Leslie B Lee
Lori S Friedman
Marcia Belvin
Megan Berry
Wei Wei Prior
P304
P356
10.1158/0008-5472.CAN-09-2525
P407
P577
2010-01-26T00:00:00Z